2024
Challenges and recommendations for the translation of biomarkers of aging
Herzog C, Goeminne L, Poganik J, Barzilai N, Belsky D, Betts-LaCroix J, Chen B, Chen M, Cohen A, Cummings S, Fedichev P, Ferrucci L, Fleming A, Fortney K, Furman D, Gorbunova V, Higgins-Chen A, Hood L, Horvath S, Justice J, Kiel D, Kuchel G, Lasky-Su J, LeBrasseur N, Maier A, Schilling B, Sebastiano V, Slagboom P, Snyder M, Verdin E, Widschwendter M, Zhavoronkov A, Moqri M, Gladyshev V. Challenges and recommendations for the translation of biomarkers of aging. Nature Aging 2024, 4: 1372-1383. PMID: 39285015, DOI: 10.1038/s43587-024-00683-3.Peer-Reviewed Original ResearchDisorders due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders due to Substance Use: Stimulants. 2024, 2843-2932. DOI: 10.1007/978-3-030-51366-5_26.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequencesBeyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder
Page C, Epperson C, Novick A, Duffy K, Thompson S. Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder. Molecular Psychiatry 2024, 29: 3802-3813. PMID: 38816586, PMCID: PMC11692567, DOI: 10.1038/s41380-024-02625-2.Peer-Reviewed Original ResearchDepressive disorderTreatment of MDDEmotional brain circuitsMental health crisisMonoaminergic antidepressantsSerotonergic antidepressantsEmotional processingDeficit hypothesisBrain circuitsMDDBehavioral functionsHypothesis explanationAntidepressantsInsufficient supportive evidenceSerotoninNeuromodulation techniquesPreclinical researchNegative biasDisordersPersistent negative biasSupportive evidenceCliniciansPsychotherapyEffective treatmentPsychedelicsChallenges in IBD Research 2024: Preclinical Human IBD Mechanisms
Ciorba M, Konnikova L, Hirota S, Lucchetta E, Turner J, Slavin A, Johnson K, Condray C, Hong S, Cressall B, Pizarro T, Hurtado-Lorenzo A, Heller C, Moss A, Swantek J, Garrett W. Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms. Inflammatory Bowel Diseases 2024, 30: s5-s18. PMID: 38778627, PMCID: PMC11491665, DOI: 10.1093/ibd/izae081.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseasePreclinical human IBD mechanismsInflammatory bowel disease researchHuman inflammatory bowel diseaseCell statesRisk allelesUnmet medical needExtraintestinal manifestationsPrecision medicineInflammatory bowel disease complicationsPreclinical researchBowel diseasePragmatic clinical researchMultidisciplinary inputBarrier functionDisease researchEnvironmental triggersMedical needClinical researchTranslational scientistsMicrobiomeAllelesEpigeneticsGeneticsRemission
2023
Dysregulation of the endogenous cannabinoid system following opioid exposure
Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.Peer-Reviewed Original ResearchConceptsEndocannabinoid systemECS componentsBrain regionsNovel neurobiological targetsTreatment of OUDEndogenous opioid systemOpioid-related deathsEndogenous cannabinoid systemSpecific brain regionsECS dysregulationOpioid exposureOUD treatmentOpioid systemCannabinoid systemNeurobiological targetsNew medicationsPreclinical literatureCannabinoid receptorsEndogenous ligandTherapeutic potentialStudy typePresent potential targetsExposure protocolOpioidsPreclinical researchA multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia
Sri S, Greenstein A, Granata A, Collcutt A, Jochems A, McColl B, Castro B, Webber C, Reyes C, Hall C, Lawrence C, Hawkes C, Pegasiou-Davies C, Gibson C, Crawford C, Smith C, Vivien D, McLean F, Wiseman F, Brezzo G, Lalli G, Pritchard H, Markus H, Bravo-Ferrer I, Taylor J, Leiper J, Berwick J, Gan J, Gallacher J, Moss J, Goense J, McMullan L, Work L, Evans L, Stringer M, Ashford M, Abulfadl M, Conlon N, Malhotra P, Bath P, Canter R, Brown R, Ince S, Anderle S, Young S, Quick S, Szymkowiak S, Hill S, Allan S, Wang T, Quinn T, Procter T, Farr T, Zhao X, Yang Z, Hainsworth A, Wardlaw J. A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia. Cerebral Circulation - Cognition And Behavior 2023, 5: 100189. PMID: 37941765, PMCID: PMC10628644, DOI: 10.1016/j.cccb.2023.100189.Peer-Reviewed Original ResearchVascular cognitive impairmentAlzheimer's diseaseAD brain pathologySmall vessel diseaseClinical featuresMixed pathologyMost dementiasVascular dementiaVessel diseaseVascular contributionsBrain pathologyCognitive impairmentDementiaPreclinical researchOlder peopleDiseasePathologyCommon typeDementia researchHuman pathologiesVCI modelPathogenesisEtiologyImpairmentDisorders Due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders Due to Substance Use: Stimulants. 2023, 1-90. DOI: 10.1007/978-3-030-42825-9_26-1.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequencesAnti-tumor Efficacy of CD19 CAR-T in a Raji B Cell Xenografted Mouse Model
Xiao Q, Su X. Anti-tumor Efficacy of CD19 CAR-T in a Raji B Cell Xenografted Mouse Model. Bio-protocol 2023, 13: e4655. PMID: 37113332, PMCID: PMC10127058, DOI: 10.21769/bioprotoc.4655.Peer-Reviewed Original ResearchCAR T cellsCD19 CAR T cellsRefractory B-cell malignanciesCell-induced tumorsChimeric antigen receptorImmune-deficient miceAnti-tumor efficacyB-cell malignanciesMouse xenograft modelTumor-killing abilityXenografted mouse modelCAR-TsT therapyHealthy donorsCD19-CARMouse modelXenograft modelTumor growthPreclinical researchTumor cellsCancer treatmentAntigen receptorMiceCellsMalignancyProtein degraders enter the clinic — a new approach to cancer therapy
Chirnomas D, Hornberger K, Crews C. Protein degraders enter the clinic — a new approach to cancer therapy. Nature Reviews Clinical Oncology 2023, 20: 265-278. PMID: 36781982, PMCID: PMC11698446, DOI: 10.1038/s41571-023-00736-3.Peer-Reviewed Original ResearchConceptsPhase III trialsCancer therapyNovel therapeutic modalitiesIII trialsClinical trialsPreclinical modelsClinical studiesTherapeutic modalitiesPharmacokinetic dataSmall molecule inhibitorsDisease pathogenesisClinical testingTumor typesDrug concentrationsPreclinical researchCancer treatmentPhase IFirst safetyUbiquitin-proteasome systemPatientsProtein degradersTherapyMore evidenceTrialsRigorous evaluation
2022
Returning to basic principles to develop more effective treatments for central nervous system disorders
Wexler BE. Returning to basic principles to develop more effective treatments for central nervous system disorders. Experimental Biology And Medicine 2022, 247: 856-867. PMID: 35172621, PMCID: PMC9158240, DOI: 10.1177/15353702221078291.Peer-Reviewed Original ResearchConceptsCentral nervous systemPositron emission tomographyNeuroplastic processesMagnetic stimulationCentral nervous system disordersFunctional magnetic resonance imaging (fMRI) imagingNervous system disordersMagnetic resonance imaging (MRI) imagingSystem-based initiativesCNS diseasesClinical trialsEffective treatmentSystem disordersSide effectsNervous systemNew treatmentsClinical disordersCandidate drugsEmission tomographyBrain functionPreclinical research
2021
A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models
Kauke M, Safi AF, Panayi AC, Palmer WJ, Haug V, Kollar B, Nelms L, Tchiloemba B, Pomahac B. A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models. Journal Of Plastic Reconstructive & Aesthetic Surgery 2021, 75: 586-604. PMID: 34895853, DOI: 10.1016/j.bjps.2021.11.003.Peer-Reviewed Original ResearchConceptsSystematic reviewImmunomodulatory strategiesPreclinical researchAvailable immunosuppressive regimensCurrent standard regimenSystemic side effectsDrug-based approachesMeta-Analyses (PRISMA) guidelinesVCA modelPreferred Reporting ItemsHind limb modelNovel immunomodulatoryRejection episodesAcute rejectionImmunosuppressive regimensStandard regimenAllograft acceptanceAlloimmune responseSuppression therapyImmunomodulation strategiesLimb transplantsPreclinical modelsRat modelHuman trialsTherapeutic approachesA digital pathology tool for quantification of color features in histologic specimens
Reschke M, DiRito JR, Stern D, Day W, Plebanek N, Harris M, Hosgood SA, Nicholson ML, Haakinson DJ, Zhang X, Mehal WZ, Ouyang X, Pober JS, Saltzman WM, Tietjen GT. A digital pathology tool for quantification of color features in histologic specimens. Bioengineering & Translational Medicine 2021, 7: e10242. PMID: 35111944, PMCID: PMC8780932, DOI: 10.1002/btm2.10242.Peer-Reviewed Original ResearchTissue samplesColor featuresPathologic featuresDistinct color featuresTissue-based analysisHistologic specimensDigital pathology toolsHistologic samplesExperienced pathologistsImage analysis algorithmsHistologic sectionsPreclinical researchHistological analysisHistological samplesImage analysis toolsCryopreserved tissuesColor thresholdingBetter rigorAnalysis algorithmPathology toolsAnalysis toolsClear needImage assessmentWhole sampleHand tracingImpact of Stress on Epilepsy: Focus on Neuroinflammation—A Mini Review
Espinosa-Garcia C, Zeleke H, Rojas A. Impact of Stress on Epilepsy: Focus on Neuroinflammation—A Mini Review. International Journal Of Molecular Sciences 2021, 22: 4061. PMID: 33920037, PMCID: PMC8071059, DOI: 10.3390/ijms22084061.Peer-Reviewed Original ResearchConceptsImpact of stressChronic stressPsychiatric comorbidityPsychiatric comorbiditiesStressor durationDepressive stateAcute stressPoor quality of lifeBrain damageSeizure occurrencePreclinical researchSeizure triggersOutcome severityDisordersEpilepsy outcomeEpilepsy patientsRecurrent seizuresEpilepsyNeurological disordersQuality of lifeSeizuresDeleterious impactDepressionComorbidity
2020
The Promise of Automated Home-Cage Monitoring in Improving Translational Utility of Psychiatric Research in Rodents
Mingrone A, Kaffman A, Kaffman A. The Promise of Automated Home-Cage Monitoring in Improving Translational Utility of Psychiatric Research in Rodents. Frontiers In Neuroscience 2020, 14: 618593. PMID: 33390898, PMCID: PMC7773806, DOI: 10.3389/fnins.2020.618593.Peer-Reviewed Original ResearchStem Cell Therapy for Stroke
Robert S, Matouk C. Stem Cell Therapy for Stroke. 2020, 331-345. DOI: 10.1007/978-3-030-56954-9_15.ChaptersTissue plasminogen activatorCell therapyIntravenous tissue plasminogen activatorSurvival of patientsPost-ischemic brainCause of disabilityDevastating neurological disorderEffectiveness of treatmentStem cell therapyMechanical thrombectomyAcute settingSafety profileFunctional outcomeBrain damageCurrent treatmentBlood flowAnimal modelsPromising treatmentNeurological disordersBrain vasculaturePreclinical trialsStrokeTherapyPreclinical researchPatients
2019
Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman A, White JD, Wei L, Johnson FK, Krystal JH. Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development. Methods In Molecular Biology 2019, 2011: 3-22. PMID: 31273690, PMCID: PMC6895673, DOI: 10.1007/978-1-4939-9554-7_1.Peer-Reviewed Original ResearchConceptsPreclinical researchAnimal modelsPsychiatric conditionsLower clinical success ratesClinical success rateCommon psychiatric conditionsPsychiatric clinical trialsClinical trialsNew pharmacotherapiesMore effective interventionsPreclinical workPsychiatric disordersPsychiatric pathophysiologyMental illnessSystematic reviewEffective interventionsAnimal experimentsDrug development processSuccess rateDrug developmentHuman psychopathologyPharmaceutical companiesPredictive validityLarge pharmaceutical companiesAnimals
2018
The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive Disorder
Adams T, Kelmendi B, Brake C, Gruner P, Badour C, Pittenger C. The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive Disorder. Chronic Stress 2018, 2: 2470547018758043. PMID: 29527593, PMCID: PMC5841259, DOI: 10.1177/2470547018758043.Peer-Reviewed Original ResearchOnset of symptomsOCD symptomatologyNeuronal hypertrophyNeuronal atrophyPathophysiological relationshipLimbic circuitsLimbic circuitryFrontal cortexDorsolateral striatumPsychosocial stressGoal-directed learningNeural abnormalitiesPsychiatric symptomatologyDorsomedial striatumPreclinical researchNonspecific factorsRole of stressSymptomsCompulsive disorderSymptomatologyStriatumOCD symptomsPathogenesisIndependent causeTraumatic incidents
2017
BET inhibitors: a novel epigenetic approach
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Annals Of Oncology 2017, 28: 1776-1787. PMID: 28838216, DOI: 10.1093/annonc/mdx157.Peer-Reviewed Original ResearchConceptsBET inhibitorsHDAC inhibitorsEpigenetic agentsExtra-terminal motif (BET) proteinsImmune checkpoint inhibitorsEarly clinical trialsNovel epigenetic approachHistone deacetylaseZeste homolog 2BET proteinsMonotherapy activityCheckpoint inhibitorsTargeted agentsPreclinical dataClinical trialsDrug classesDrug combinationsSingle agentSolid tumorsPreclinical researchTumor cellsHomolog 2Lysine-specific demethylase 1Anticancer therapyInhibitorsMagnetoencephalography as a Tool in Psychiatric Research: Current Status and Perspective
Uhlhaas P, Liddle P, Linden D, Nobre A, Singh K, Gross J. Magnetoencephalography as a Tool in Psychiatric Research: Current Status and Perspective. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2017, 2: 235-244. PMID: 28424797, PMCID: PMC5387180, DOI: 10.1016/j.bpsc.2017.01.005.Peer-Reviewed Original ResearchPsychiatric researchAberrant rhythmic activityAbnormal brain dynamicsAutism spectrum disorderNeurobiological mechanismsPsychiatric conditionsCircuit dysfunctionNeuropsychiatric disordersNeuropsychiatric conditionsSpectrum disorderApplication of magnetoencephalographyNeural oscillationsBrain dynamicsMagnetoencephalographyNeuronal eventsPreclinical researchDisordersMEG signalsMillisecond resolutionDevelopment of biomarkersSchizophreniaPathophysiological mechanismsPsychiatricAutismTranslational researchA Murine Model to Study Epilepsy and SUDEP Induced by Malaria Infection
Ssentongo P, Robuccio A, Thuku G, Sim D, Nabi A, Bahari F, Shanmugasundaram B, Billard M, Geronimo A, Short K, Drew P, Baccon J, Weinstein S, Gilliam F, Stoute J, Chinchilli V, Read A, Gluckman B, Schiff S. A Murine Model to Study Epilepsy and SUDEP Induced by Malaria Infection. Scientific Reports 2017, 7: 43652. PMID: 28272506, PMCID: PMC5341121, DOI: 10.1038/srep43652.Peer-Reviewed Original ResearchConceptsCerebral malariaAnimal modelsStrain combinationsPrevention of epilepsySuch animal modelsSubsequent epilepsyNeurological sequelaeAdjunctive therapyPathophysiological mechanismsMalaria infectionUnexpected deathMurine modelEpilepsyPreclinical researchSUDEPMalariaGenetic backgroundMultiple miceEpileptogenesisSequelaeTherapyInfectionMiceSurvivorsPrevention
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply